Atomera Incorporated vs GSK plc — how do they compare? Atomera Incorporated trades at $5.57 (market cap $209.56M), while GSK plc trades at $51.15 (market cap $104.15B). The key difference: GSK plc is far larger — about 497× Atomera Incorporated's market cap, and GSK plc pays a 3.48% dividend while Atomera Incorporated pays none. Which is the better fit depends on your goals.
| ATOM | GSK | |
|---|---|---|
Market Cap | $209.56M | $104.15B |
Sector | Technology | Health |
52-Week High | $12.11 | $61.18 |
52-Week Low | $1.99 | $37.71 |
Enterprise Value | $172.37M | $124.56B |
Dividend Yield | — | 3.48% |
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $5.48, up 3.1% today, but faces significant fundamental challenges with a P/S ratio of 797.66 and deeply negative profitability metrics including a -78.7% gross margin and -9,742% net income margin. The company has missed earnings expectations for three consecutive quarters while technical indicators show bearish momentum with RSI signaling overbought conditions at 78.05. Recent news highlights progress in semiconductor technology licensing but financial performance remains weak.
Despite unanimous analyst buy ratings, ATOM presents high-risk exposure due to substantial losses, negative cash flow, and elevated valuation multiples. The semiconductor licensing business shows technological promise but requires significant revenue acceleration to justify current valuation. Near-term catalysts depend on commercial adoption breakthroughs while downside risk remains elevated given current financial metrics.
GSK trades at $52.96, up 1.51% today, with strong technical momentum showing bullish moving averages and neutral oscillators. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $1.36 beating estimates by 7%. Recent FDA approval for Jideytro lung cancer therapy and a $2.52 billion cost-saving initiative support growth prospects. Valuation metrics remain reasonable with P/E of 16.69 and EV/EBITDA of 9.68.
GSK presents a balanced investment case with solid fundamentals and pipeline progress offset by margin pressure risks. The company's 29.73% ROE and consistent dividend payments provide shareholder value, while competitive pressures and patent expirations require careful monitoring. Analyst consensus leans Hold (55%) with 31% Buy ratings, suggesting cautious optimism for the pharmaceutical giant's transformation under new leadership.
Trailing returns across standard periods
Latest headlines on both assets
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →